imtesty, thank you for that. I guess it's better to be safe than sorry, God forbid a patient dies in the open-label study because of what now came to light if found to be correct. That could potentially be the end of apabetalone as it has failed two trials before. That will make it harder to go on with BOM2 as it would set us back considerably if there be anything left to go on with to fight another day. 

Now I'm hoping that Resverlogix responds to the two articles that have been brought to the forefront in this ever-revolving roller coaster saga. And then again we may not hear anything from Resverlogix until the articles are peer-reviewed and that may take some time. These articles are dated Nov 15, 2021, so I'm sure Resverlogix is made aware of this, hence potentially contributing to further delays in the start of dosing patients.

Koo